lapatinib has been researched along with Leishmania Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiebchun, T; Choowongkomon, K; Kiriwan, D; Rasri, N; Siripattanapipong, S | 1 |
| Croft, SL; Sanderson, L; Yardley, V | 1 |
2 other study(ies) available for lapatinib and Leishmania Infection
| Article | Year |
|---|---|
In Vitro and In Silico Studies of Kinase Inhibitor of MAPK3 Protein to Determine Leishmania martiniquensis Treatment.
Topics: Afatinib; Animals; Antineoplastic Agents; Antiprotozoal Agents; Escherichia coli; Female; Lapatinib; Leishmania donovani; Leishmaniasis; Protein Kinase Inhibitors | 2023 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |